Method for establishing the sensitivity of tumours to capecitabin and test kit

Method according to one of the aforementioned claims, wherein the gene expression or the biological function of thymidine phosphorylase and/or cyclooxygenase 2 and/or VEGF and VEGF receptors is determined.

Method according to one of the aforementioned claims, wherein the tumor tissue or parts thereof are put in contact with at least one substance which has been at least partly dissolved, manifesting affinity to the gene of human thymidine phosphorylase and/or to variants and/or to parts thereof and/or to its mRNA and/or to its genetic products and/or cleavage products, polypeptides or peptides derived therefrom, and/or is brought into contact with at least one substance manifesting affinity to the gene of human cyclooxygenase 2 and/or to variants and/or to parts thereof and/or to its mRNA and/or to its genetic products and/or cleavage products, polypeptides or peptides derived therefrom, and/or is brought into contact with at least one substance manifesting affinity to the gene of human VEGF and human VEGF receptor and/or to variants and/or to parts thereof and/or to its mRNA and/or to its genetic products and/or cleavage products, polypeptides or peptides derived therefrom.

Test kit for identification of a human tumor which is sensitive or insensitive with a view to capecitabine, if applicable in combination with Docetaxel, Paclitaxel or Herceptin or a COX-2 inhibitor, preferably Celebrex, wherein it contains at least one soluble substance manifesting affinity to the gene of human thymidine phosphorylase and/or to variants and/or to parts thereof and/or to its mRNA and/or to its genetic products and/or cleavage products, polypeptides or peptides derived therefrom and/or it contains at least one substance manifesting affinity to the gene of human cyclooxygenase 2 and/or to variants and/or to parts thereof and/or to its mRNA and/or to its genetic products and/or cleavage products, polypeptides or peptides derived therefrom and/or it contains at least one substance manifesting affinity to the gene of human VEGF and human VEGF receptor and/or to variants and/or to parts thereof and/or to its mRNA and/or to its genetic products and/or cleavage products polypeptides or peptides derived therefrom.

Use of capecitabine and at least one COX-2 inhibitor and/or one angiogenesis inhibitor for the manufacture of a drug against a human tumor, in particular against a metastatic tumor of the large intestine or the breast or any other solid tumor.